"Dr. Zhao, is there any way you can think of to help?"

Ma Jianteng's words were almost a plea, something he hadn't done in a long time.

"Let's conduct an examination first when you return. I can't say whether there is a way or not until I understand the situation."

Zhao Heng thought for a moment before speaking slowly.

From ancient times, treating high-ranking officials was never a doctor's favorite task.

As seen in historical court dramas, whenever someone close to the emperor falls ill, be it a prince or the emperor's favorite concubine, the first thing the emperor says to the visiting doctor is, "If you can't cure him, neither will you live."

Imagine, when hearing such words while treating a patient, which doctor can still calmly focus on the treatment?

As for martial arts dramas where a doctor is killed for not curing a disease, those exist too.

It's not that editors have lost their minds; even in modern society, incidents of patients killing doctors occur frequently!

"Alright, Dr. Zhao."

Upon hearing Zhao Heng's words, Ma Jianteng felt slightly disappointed, but gained a bit of confidence in Zhao Heng's expertise. This hint of confidence stemmed from his unwillingness to give up on treating his child.

He wouldn't give up as long as there was the slightest chance.

Despite his status and wealth, worldly pleasures mean little to him; in terms of fatherly love, he is no different from any other father.

"Actually, the most challenging aspect of treating brain gliomas is that drugs cannot directly reach the lesion. I've read some literature suggesting the development of a new type of non-cationic siRNA nanomedicine - siRNA micelles. These siRNA micelles demonstrate good blood circulation time, cellular uptake ability, and drug-loading capacity. Most importantly, they can directly carry drugs across the blood-brain barrier to effectively reach the glioma location."

Zhao Heng pondered briefly before speaking slowly again.

This highlights the benefits of pooling all doctors' experiences in Eastern Hospital; sometimes in clinical practice, the hardest part is clinical thinking.

The human body is complex and mysterious, and developing a method might be needed for treating certain diseases.

For brain gliomas, the Mayo Clinic leans more towards surgical treatment, with little in-depth research on drug-loading carriers.

Surgical treatment is a more direct approach compared to drug therapy, excelling in high-tech electronics and mechanical engineering.

In electronics and mechanics, the Beautiful Country is top-notch.

"I've read this paper too. The siRNA micelles can effectively cross the blood-brain barrier without specific targeting ligand modifications. Moreover, due to their non-cationic nature, they exhibit no charge-related toxicity, showing good biocompatibility and promising potential for clinical application."

Upon hearing Zhao Heng's words, Dean spoke suddenly.

Dean Liu Shangming is a giant in the field of oncology and naturally has profound knowledge of difficult-to-treat cancers like gliomas.

"Dr. Zhao, Dean Liu, has anyone in the country developed these siRNA micelles? If not domestically, is there any laboratory worldwide that has developed them?"

Upon hearing Zhao Heng and Dean Liu Shangming's words, Ma Jianteng clung to them like grasping a straw, speaking eagerly.

Actually, Ma Jianteng didn't have high hopes when coming to Eastern Hospital and finding Zhao Heng; even the world's best hospital, Mayo Clinic, couldn't cure his son's illness. How can domestic hospitals and doctors do so?

Nevertheless, he still harbors a sliver of hope in his heart.

"As of now, no laboratory domestically or globally has developed siRNA micelles for clinical use."

Dean Liu Shangming regrettably stated first. Although he is a dean, he is primarily a doctor, thus unable to speak ambiguously; the situation is as it is.

Even though Ma Jianteng is the richest man with assets worth billions, Eastern Hospital, as the country's top large hospital, also has assets worth billions, with annual revenues in the hundreds of billions.

Therefore, facing Ma Jianteng, Liu Shangming isn't intimidated; it's not him to grovel before wealthy people.

"Professor Li Hongwei's research in nano-therapy is among the best worldwide. Although siRNA micelles aren't within Professor Li Hongwei's research scope, if specific technical support is invested, I believe it's possible to develop siRNA micelles in a short time."

Zhao Heng thought seriously and said.

Research across disciplines is interconnected.

Since Professor Li Hongwei's research in nano-therapy is very profound, studying this siRNA micelle preparation is still feasible.

"The timeframe is so short, the difficulty of development is high indeed."

Dean Liu Shangming couldn't help but remark. It's not that he doubts Professor Li Hongwei's capability but considering Ma Jianteng's son's condition; realistically speaking, he has less than two months left.

To develop a never-before-seen siRNA micelle ready for immediate clinical use within such a short time is exceedingly difficult.

Moreover, there's no certainty that Professor Li Hongwei can spare two months from his national-level key research project to focus solely on developing siRNA micelles.

"If it's just one person, the development time is indeed insufficient, but I've learned a few things from Professor Li Hongwei and can probably expedite this development process."

Zhao Heng said.

He stated this because, last time during his visit to Professor Li Hongwei's laboratory, Professor Li shared something with him.

Namely, Professor Li Hongwei's research project is currently in dire need of funding support.

Upon hearing this, Zhao Heng was puzzled; how could a researcher of Professor Li Hongwei's caliber receive state-level attention yet lack funding support?

At that time, Professor Li Hongwei merely smiled wryly at Zhao Heng, saying state funding is indeed limited. Since biomaterial technology isn't part of the state's science strategy focus, the current priority still lies in aerospace.

Adding to the fact that Professor Li Hongwei's research in nano-therapy is highly advanced, with clinical application requiring time for development, generating economic benefits isn't ideal.

This led some large pharmaceutical companies domestically not to favor investing in Professor Li Hongwei's research, unwilling to invest substantial development funds.

To these pharmaceutical companies, investing funds into nano-therapy, which won't yield returns within years, is less efficient than importing a hypertension drug, repackaging it, and generating quick profits.

Even combining certain vitamins into a health supplement can quickly generate money.

Thus, Zhao Heng mentioning Professor Li Hongwei in front of Ma Jianteng was intended to scrounge some research funds for him.

It's understandable.

"Dr. Zhao, if Professor Li Hongwei's laboratory can develop this siRNA micelle in a short timeframe, I'm willing to invest ten billion, no, a hundred billion into this research. If one hundred billion isn't enough, tell me how much is needed; I'll surely satisfy it. Don't laugh; now, even the slightest glimmer of hope, I don't wish to give up."

Upon hearing this, Ma Jianteng felt hopeful again and quickly expressed his stance.

Prior to coming, his media team conducted a thorough investigation of Zhao Heng, concluding he is a prodigious talent in medicine, constantly creating miracles!

Moreover, with Zhao Heng mentioning Professor Li Hongwei, Ma Jianteng felt even more hopeful, considering Professor Li Hongwei is currently a hot scientist in the bioscience world and a promising winner of this year's National Science Progress Award!

If you find any errors ( broken links, non-standard content, etc.. ), Please let us know < report chapter > so we can fix it as soon as possible.